Bourla called and Coric answered: Pfizer's offer for Biohaven slid $10.50 per share in under 30 days but added spinoff funds, royalties
After having secured a licensing collaboration with Pfizer for its migraine franchise outside the US in November 2021, Biohaven was on the hunt for additional partners. One party, a “multinational biopharmaceutical,” was in negotiations with Biohaven in February 2022.
But an April 11 evening phone call from Albert Bourla changed Biohaven’s trajectory. The Pfizer CEO dialed Biohaven CEO Vlad Coric to share his interest in a takeover, according to new details revealed in an SEC filing. Within 30 days, the companies disclosed an $11.6 billion deal opening the doors to a massive migraine portfolio for the Covid vaccine juggernaut.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.